An experimental drug called daraxonrasib nearly doubled overall survival rates for some patients with advanced pancreatic cancer in a recent clinical trial [1].

This development is significant because pancreatic cancer is among the most lethal malignancies, often resisting standard treatments. The new drug provides a potential lifeline for patients who have already seen standard chemotherapy fail [3].

The trial was a global study coordinated through the Massachusetts General Hospital (MGB) Cancer Institute [1, 2]. The results of the study were reported in May 2024 [1, 2].

Daraxonrasib works by targeting the KRAS G12D mutation [3, 4]. This specific genetic mutation drives the growth of most pancreatic cancers, making it a primary target for precision medicine. By inhibiting this mutation, the drug aims to slow the progression of the disease in patients with advanced stages of the cancer.

Medical professionals noted the impact of the trial on patient outcomes. "The drug daraxonrasib nearly doubled overall survival in patients with advanced pancreatic cancer," said Dr. Harsh Singh, program director at the MGB Cancer Institute [2].

The data indicated that the overall survival rate was nearly doubled, an approximately two-fold increase, compared to previous benchmarks [1]. The study focused on patients whose cancer had progressed despite the use of conventional chemotherapy [3].

Researchers continue to monitor the long-term effects of the treatment as it moves through the clinical pipeline. The global nature of the study allowed the MGB Cancer Institute to gather a diverse set of patient data to verify the drug's efficacy across different populations [1, 2].

“The drug daraxonrasib nearly doubled overall survival in patients with advanced pancreatic cancer”

The success of daraxonrasib represents a shift toward precision oncology in treating pancreatic cancer. By targeting the KRAS G12D mutation specifically, researchers are moving away from broad-spectrum chemotherapy toward therapies tailored to the genetic profile of the tumor. If these results are replicated in larger cohorts, it could establish a new standard of care for advanced patients who previously had few remaining treatment options.